Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1B | P68106 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | PPIA | P62937 | 17/20 | 0.44 |
| ▸ | PPIB | P23284 | 15/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PPIF | P30405 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976362 | 0.93 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976357 | 0.91 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976358 | 0.90 | FKBP1B (0.45) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976368 | 0.89 | FKBP1B (0.44) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976361 | 0.88 | FKBP1B (0.53) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976363 | 0.86 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976354 | 0.86 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976364 | 0.85 | FKBP1B (0.46) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL9976367 | 0.83 | PPP3CA (0.52) | FKBP1BABCB1PPIAPPIBSLCO1B1 | |
| SCHEMBL16267643 | 0.82 | ABCB1 (0.68) | FKBP1BABCB1PPIAPPIBSLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | FKBP1B 138/4885ABCB1 70/4885PPIA 812/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | FKBP1B 141/4885ABCB1 68/4885PPIA 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.